In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Selzentry HIV Drug Faces India Opposition As Too Expensive (India)

This article was originally published in PharmAsia News

Executive Summary

Patient groups and two organizations are challenging the patent India gave to Pfizer for its Selzentry (maraviroc), one of a new class of oral AIDS drugs intended as second-line treatments. Medicines Sans frontiers and a Mumbai lawyer group are poring over the patent grant to see if it was justified, with an eye to questions raised about the drug by Europe's patent office. Challengers have a year from last June to mount an official challenge to granting a patent right. The U.S. FDA approved the drug in August. (Click here for more

You may also be interested in...



QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.

New China Drug Regulation Legalizes Emergency Approval Mechanism

The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.

UsernamePublicRestriction

Register

SC065874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel